However, the changes of CD8+/CD4+ T cells ratio were not evident between toripalimab group and IgG4 group in ccRCC-02_PDO and ccRCC-04_PDO, suggesting failure of expanding CD8+ T cells after anti PD-1 treatment (Fig. 3A, 3C). Here, CD8A is linked to nonpapillary renal cell carcinoma.